Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
about
Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safetyDevelopments in Intralesional Therapy for Metastatic MelanomaTopical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis.Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.Toll-like receptor agonists in cancer therapy.A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma.Current treatment of locoregional recurrence of melanoma.The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review.Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomasTrial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Local therapy of cancer with free IL-2.Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy.Dendritic cell vaccination as a treatment modality for melanoma.Intratumoral immunization: a new paradigm for cancer therapy.Velimogene aliplasmid.Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology.Microinvasive melanoma: cutaneous pharmacotherapeutic approaches.Intra-lesional interleukin-2 therapy for in transit melanoma.Intralesional therapy for metastatic melanoma.Advances in Toll-like receptor biology: Modes of activation by diverse stimuli.Toll-like receptors and cutaneous melanoma.The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy.Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream.Treatment of cutaneous melanoma: current approaches and future prospects.Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.Re-inventing intratumoral immunotherapy for melanoma.Intratumoral immunotherapy: using the tumor as the remedy.Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial.Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease
P2860
Q24633360-88DF22F1-7455-49F6-9C5D-BFD97BA8B230Q28069615-5E45ED92-A157-4769-A277-8999F79B6AAAQ30276126-A0AA90E3-96F5-4B11-86B7-D09DE2FE2E9BQ30433673-7D618E6A-9A10-49C4-8268-C57D406DC06BQ33293591-667F938F-0055-4468-AC7F-8F4BC81C8672Q33918509-F2FD7C40-B6C8-483E-BDE2-777ECDF97193Q34417540-A325A051-8071-47F2-B919-A3E336489A18Q34888462-54DF0188-A253-4F14-9848-BA6B1200D511Q35018021-3E21C52A-CFA0-4439-80DC-D345464EAC50Q35201353-1A773A4A-ADE4-42BF-951E-7BFE642DF013Q35231246-B0798845-3E8D-4746-82AF-A862906892F0Q35845352-24F27408-01C3-448A-BF80-1FBF51F0FC92Q36373370-38207315-D7BD-4365-864D-F5F466D08000Q36585434-E94B5847-F5BE-4D45-9E96-99595E9ABD7CQ37628065-A9874919-AF2A-40C6-A5E1-E1EC7CA595FAQ37628701-CFDBB07D-D341-487F-B6A3-33C8B08FBE1EQ37691837-7973E8D7-CA5B-487B-A699-B7D13DD5C028Q37724340-A7C73196-15F9-4D53-822E-A8D1DB3ABDF7Q37725792-2590741D-A8B5-437E-B1CA-D7FA5AB47535Q38088212-46816025-40A1-4F1B-BA24-954C8F2CFC07Q38181030-510F6E23-69E6-4DDF-89A3-E08272963780Q38266193-1DE60399-3742-496E-86B4-EFA7BEC45496Q38413291-01154DA2-02CF-47F4-A80A-492DF18CE49EQ39023996-EFF64DC2-D402-43F3-A79A-FA218964B64AQ39157489-7094D893-BC33-44CF-83D1-F5616650E897Q39589846-83865400-BB0E-420C-8FC6-D41A676288A8Q39801051-63D33972-7B1F-4B59-ADF6-A00505807DEEQ41349651-621A2AB8-377E-4E4A-94DB-E1E9F16525DAQ44607083-DB317EB2-463C-4F7B-8FA6-8487F53FE3CAQ47281370-F0D1AF47-DB00-47B1-9BF4-536942461340Q52597538-6F86708C-7FBE-45D8-A93D-460B023FD63AQ58317803-D1B47CDB-596D-41C2-B6CD-449E041BCD6D
P2860
Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Phase I/II study of topical im ...... astases in malignant melanoma.
@en
Phase I/II study of topical im ...... astases in malignant melanoma.
@nl
type
label
Phase I/II study of topical im ...... astases in malignant melanoma.
@en
Phase I/II study of topical im ...... astases in malignant melanoma.
@nl
prefLabel
Phase I/II study of topical im ...... astases in malignant melanoma.
@en
Phase I/II study of topical im ...... astases in malignant melanoma.
@nl
P2093
P2860
P1476
Phase I/II study of topical im ...... astases in malignant melanoma.
@en
P2093
A G Dalgleish
M D Bodman-Smith
M D Fischer
P2860
P304
P356
10.1111/J.1365-2133.2006.07664.X
P407
P577
2007-02-01T00:00:00Z